Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
1.760
+0.050 (2.92%)
Feb 21, 2025, 4:00 PM EST - Market closed
Immuneering Stock Forecast
IMRX's stock price has decreased by -73.96% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Immuneering stock have an average target of 12.2, with a low estimate of 3.00 and a high estimate of 25. The average target predicts an increase of 593.18% from the current stock price of 1.76.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Immuneering stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +581.82% | Feb 6, 2025 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +752.27% | Jan 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +638.64% | Jan 8, 2025 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +752.27% | Jan 7, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +638.64% | Nov 20, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.95
from -1.88
EPS Next Year
-1.63
from -1.95
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | n/a | |||
| Avg | n/a | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.74 | -0.97 | -1.28 | |||
| Avg | -1.95 | -1.63 | -1.98 | |||
| Low | -2.14 | -2.21 | -2.48 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.